Ambrx Biopharma, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
10975 North Torrey Pines Road, La Jolla, CA
Fiscal year end
December 31
Former names
New Ambrx Biopharma Inc. (to 9/15/2023)
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.2M shares
Common Stock, Value, Issued 6K USD
Weighted Average Number of Shares Outstanding, Basic 62.3M shares +61.2%
Weighted Average Number of Shares Outstanding, Diluted 62.3M shares +61.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 53K USD -96.7%
Revenue from Contract with Customer, Excluding Assessed Tax 53K USD -96.7%
Research and Development Expense 16.3M USD +30.7%
General and Administrative Expense 9.41M USD +84.7%
Operating Income (Loss) -25.6M USD -60.8%
Nonoperating Income (Expense) 2.79M USD +647%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.8M USD -46.7%
Income Tax Expense (Benefit) 148K USD
Net Income (Loss) Attributable to Parent -23M USD -47.7%
Earnings Per Share, Basic -0.37 USD/shares +7.5%
Earnings Per Share, Diluted -0.37 USD/shares +7.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 225M USD +341%
Accounts Receivable, after Allowance for Credit Loss, Current 122K USD
Other Assets, Current 805K USD
Assets, Current 234M USD
Property, Plant and Equipment, Net 3M USD
Operating Lease, Right-of-Use Asset 9.57M USD
Intangible Assets, Net (Excluding Goodwill) 24.8M USD
Other Assets, Noncurrent 336K USD
Assets 272M USD
Accounts Payable, Current 5.14M USD
Employee-related Liabilities, Current 3.54M USD
Accrued Liabilities, Current 10.8M USD
Liabilities, Current 18.3M USD
Contract with Customer, Liability, Noncurrent 1.75M USD
Deferred Income Tax Liabilities, Net 880K USD
Operating Lease, Liability, Noncurrent 8.61M USD
Liabilities 29.1M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -790K USD
Retained Earnings (Accumulated Deficit) -348M USD
Stockholders' Equity Attributable to Parent 242M USD +90.1%
Liabilities and Equity 272M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 136M shares
Common Stock, Shares, Issued 63M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 226M USD +335%
Depreciation 200K USD 0%
Property, Plant and Equipment, Gross 9.24M USD
Operating Lease, Liability, Current 1.92M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Operating Lease, Payments 701K USD +1.74%
Additional Paid in Capital 591M USD
Amortization of Intangible Assets 200K USD 0%
Share-based Payment Arrangement, Expense 4.82M USD +213%